Description of Collaborative Activity: |
The National Institute of Allergy and Infectious Diseases (NIAID) and Centers for Disease Control and Prevention (CDC) recognize the need to perform preclinical safety and efficacy evaluations of candidate products in the repeat low-dose (RLD) macaque SIV/SHIV infection model that has been established by CDC. NIAID established an interagency agreement with CDC to: 1) conduct safety and efficacy evaluations of Topical Microbicide/Biomedical Prevention products in the RLD macaque model, including pharmacokinetic/pharmacodynamic analyses of candidate biomedical prevention products; 2) utilize relevant macaque species, virus strains, and routes of infection to accomplish the proposed evaluations; and 3) perform other macaque studies as needed. |
